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The  endothelium  imposes  a  structural  barrier  to  the 
extravasation of systemically delivered oncolytic adeno­
virus  (Ad).  Here,  we  introduced  a  transendothelial 
route of delivery in order to increase tumor accumula­
tion of virus particles (vp) beyond that resulting from 
convection­  dependent  extravasation  alone.  This  was 
achieved by engineering an Ad encoding a syncytium­
forming protein, gibbon ape leukemia virus (GALV) fuso­
genic membrane glycoprotein (FMG). The expression of 
GALV was regulated by a hybrid viral enhancer­human 
promoter construct comprising the human cytomegalo­
virus (CMV) immediate­early enhancer and the minimal 
human  endothelial  receptor  tyrosine  kinase  promoter 
(“eTie1”). Endothelial cell­selectivity of the resulting Ad­
eTie1­GALV vector was demonstrated by measuring GALV 
mRNA  transcript  levels.  Furthermore,  Ad­eTie1­GALV 
selectively induced fusion between infected endothelial 
cells and uninfected epithelial cells in vitro and in vivo, 
allowing transendothelial virus penetration. Heterofusion 
of infected endothelium to human embryonic kidney 293 
(HEK 293) cells, in mixed in vitro cultures or in murine 
xenograft models, permitted fusion­dependent transac­
tivation of the replication­deficient Ad­eTie1­GALV, due 
to enabled access to viral E1 proteins derived from the 
HEK 293 cytoplasm. These data provide evidence to sup­
port our proposed use of GALV to promote Ad penetra­
tion through tumor­associated vasculature, an approach 
that may substantially improve the efficiency of systemic 
delivery of oncolytic viruses to disseminated tumors.
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IntroductIon
The  ability  of  intravenously  (i.v)  administered  adenoviruses 
(Ads) to infect tumor cells within cancer deposits is confounded 
by many obstacles, notably the vascular endothelium separating 
the blood circulation from the tumor parenchyma. Only a small 
fraction of the input dose of virus particles (vp) achieves extrava-
sation within solid tumors and is able to infect cancer cells.1 In 
contrast, circulating vp interact readily with the tumor-associated 
  endothelium, which is directly accessible from the blood stream. 
Because  tumor-associated  endothelial  cells  express  a  range  of 
receptors  that  allow  natural  or  retargeted  infection  by  various 
viruses, including Ad and vaccinia,2,3 targeted infection of tumor-
  associated endothelial cells may allow efficient delivery of vp to 
disseminated tumors. One of the most promising cancer gene ther-
apy approaches makes use of oncolytic viruses, however   oncolytic 
Ads are generally designed so that their replication is triggered 
by tumor-associated molecular changes.4 Accordingly they can-
not  achieve  lytic  self-amplification  within  noncancerous,  and 
therefore nonpermissive, endothelial cells. This turns the tumor 
endothelium from a potentially useful target into a significant 
structural barrier to oncolytic agents, which must gain infection 
of target tumor cells in order to fulfill their therapeutic potential.5 
This impediment could be partially overcome by conditioning the 
tumor endothelium with VEGF165 to transiently support the rep-
lication of oncolytic agents such as reovirus and vesicular stoma-
titis virus,6 or by the use of an oncolytic agent such as vaccinia 
virus  which  naturally  targets  tumor-associated  endothelium.3 
However, the activity of most oncolytic agents remain limited by 
their inability to penetrate through the endothelium. In the pres-
ent study, we investigate a new approach to achieving transend-
othelial delivery by exploiting endothelial-specific production of 
a viral fusogenic membrane glycoprotein (FMG), thereby utiliz-
ing endothelial–epithelial fusion as a means of creating an access 
route for therapeutic viruses from the blood circulation into the 
tumor parenchyma.
The use of FMGs to enhance cell-to-cell spread of oncolytic 
agents  has  been  demonstrated  in  previous  studies.7–10  FMGs 
such as gibbon ape leukemia virus (GALV) have been explored 
as therapeutic transgenes to arm oncolytic viruses, inducing the 
formation of multinucleated syncytia which may facilitate viral 
spread from infected to adjacent uninfected cells.7–10 The ability 
of FMGs to synergize with virotherapy and enhance their anti-
tumor efficacy has been demonstrated in previous studies,7,11–14 
raising  the  possibility  that  FMGs  may  function  as  effective 
cytotoxics as well as transduction agents to complement viro-
therapy. Here, we report the GALV-driven formation of hetero-
cellular syncytia between tumor-associated endothelial cells and 
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tumor cells as a means of promoting Ad penetration from the 
bloodstream  into  the  tumor.  This  was  accomplished  through 
transcriptionally directing GALV expression to activated, pro-
liferating endothelium using a construct containing a 460 base 
pair enhancer from the human cytomegalovirus (CMV) and a 
880 base pair promoter of human endothelial receptor tyrosine 
kinase (Tie1).15 Tie1 is expressed almost exclusively on endothe-
lial cells,16 mainly during embryonic vasculogenesis but also in 
adults during both physiological and tumor angiogenesis.17–22 
We engineered an Ad vector encompassing this fusogenic sys-
tem which expressed high levels of the transgene exclusively in 
endothelial  cells,  and  mediated  endothelial-tumor  cell  fusion 
in vitro and in vivo. Formation of heterocellular syncytia follow-
ing infection of endothelial cells resulted in fusion-dependent 
infection  of  human  embryonic  kidney  293  (HEK  293)  cells 
in vitro and HEK 293 xenografts in vivo, resulting in dramati-
cally increased viral titers. We have therefore provided the first 
demonstration of using heterocellular syncytium formation to 
assist  viral  penetration  through  the  tumor  vasculature,  ulti-
mately allowing target cell transduction. This strategy may be 
applicable to oncolytic Ads, e.g., AdEHE2F, vKH6, and CV706,4 
which are reliant on gain of function mutations in tumor cells, 
whereby  cancer-specific  factors  could  then  become  imported 
into endothelial nuclei-containing virus genomes to   transactivate 
replication.
results
transcriptional targeting of GAlV expression 
to angiogenic endothelium
The use of Ad to achieve the fusion of tumor-associated endothe-
lium to tumor cells requires tight transcriptional regulation to 
minimize the risk of off-target toxicity. One means of achieving 
such regulation is through the use of tissue-specific promoters. 
To select the optimum endothelial-selective promoter to drive 
GALV expression, the minimal promoter sequences of Tie115 and 
the kinase insert domain receptor (KDR) of vascular endothe-
lial growth factor23,24 were isolated from primary human umbili-
cal vein endothelial cells (HUVECs), and tested in the context 
of luciferase-expressing reporter Ads based on the AdEasy sys-
tem (Qbiogene, MP Biomedicals, Montreal, Quebec, Canada). 
Replication-deficient  vectors  were  constructed  with  each  pro-
moter cloned upstream of luciferase or GALV (Figure 1a), allow-
ing quantitative comparisons of promoter strength and cell-type 
selectivity (Figure 1b). Tie1 or KDR-driven luciferase-express-
ing reporter viruses, Ad-KDR-Luc and Ad-Tie1-Luc, were used 
to  infect  HUVECs,  human  microvascular  endothelial  cells  or 
SW480  (human  colorectal  cancer)  cells.  Activity  of  Ad-KDR-
Luc was close to background levels in all cells tested; in contrast, 
Ad-Tie1-Luc exhibited high endothelial specificity, with a 100-
fold greater luciferase expression per genome copy in HUVECs 
(P < 0.01) and human microvascular endothelial cells (P < 0.001) 
than  in  SW480  cells.  In  contrast  the  CMV  promotor  driven 
Ad-Luc control virus showed no selectivity for endothelial cells 
(P > 0.05) (Figure 1b).
However,  the  corresponding  GALV-expressing  viruses 
(Ad-Tie1-GALV and Ad-KDR-GALV) did not drive adequate 
levels of GALV expression in HUVECs to permit fusion (data 
not  shown).  We  therefore  sought  to  increase  the  functional 
output  of  the  tightly  endothelial-selective  Tie1  promoter  by 
introducing the CMV immediate-early enhancer element, pro-
ducing transcriptional control by a hybrid CMV enhancer-Tie1 
promoter (Ad-eTie1-GALV). This virus induced extensive syn-
cytium formation in cultured HUVECs, leading to loss of cell 
morphology and clustering of nuclei as shown by DAPI staining; 
tubulin organization in syncytia was shown by staining with an 
anti-α tubulin-fluorescein isothiocyanate antibody (Figure 1c). 
These effects were not observed for the control Ad-Luc vector 
(Figure 1d).
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Figure  1  construct  organization  and  promoter  optimization.  (a) 
Construction of reporter and GALV­expressing viruses: genome organiza­
tion of E1/E3­deleted adenovirus serotype 5 vectors­expressing luciferase 
or GALV under KDR or Tie1 promoter control (Ad­KDR­Luc, Ad­Tie1­Luc, 
Ad­KDR­GALV, Ad­Tie1­GALV); and a GALV­expressing vector driven by 
a hybrid CMV enhancer­human Tie1 promoter system (Ad­eTie1­GALV). 
(b) Comparison of the activity and endothelial­selectivity of Tie1, KDR, 
and CMV promoters. Luciferase expression from reporter viruses was 
assayed  at  48  hours  postinfection  with  Ad­KDR­Luc,  Ad­Tie1­Luc,  or 
Ad­Luc at 1,000 vp/cell; viral DNA was extracted from cell lysates for 
real­time quantitative PCR (QPCR) analysis. Data represent mean values 
(±SE of the mean), n = 4. Statistical analyses were performed by one­way 
ANOVA Tukey’s multiple comparison test for each vector in the three 
different cell lines, or for comparing the performance of the three vec­
tors in each cell line; **P < 0.01; ***P < 0.001. (c,d) Demonstration of 
Ad­eTie1­GALV fusogenicity. Cytoskeleton and nuclei of HUVECs infected 
with (c) Ad­eTie1­GALV or (d) Ad­Luc control were fluorescently labeled 
using an anti­α­tubulin antibody and the nuclear dye DAPI. Ad, adeno­
virus; ANOVA, analysis of variance; CMV, cytomegalovirus; GALV, gibbon 
ape leukemia virus; HUVEC, human umbilical vein endothelial cell; KDR, 
kinase insert domain receptor.Molecular Therapy  vol. 19 no. 1 jan. 2011  69
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Ad-etie1-GAlV mediates endothelial-specific  
cell–cell fusion
The  cell-type  specificity  of  the  CMV  enhancer-Tie1  promoter 
transcriptional activation system of Ad-eTie1-GALV was tested 
in a range of human cell lines including those of epithelial (PC-3, 
prostate  cancer),  mesenchymal  (MRC5v2,  immortalized  fibro-
blast and HT1080, fibrosarcoma) or endothelial (HUVEC) origin. 
As GALV-mediated fusion is dependent on the recognition of the 
cellular transmembrane receptor Pit-1,25 the ability of each of the 
nonendothelial cell lines to undergo GALV-induced homocellu-
lar fusion was tested by transfection with a control CMV-driven 
GALV-expressing  plasmid  (CMV-GALV)  (left  panel  images, 
Figure 2a). In each of these cell lines, the CMV-GALV plasmid 
induced  extensive  syncytium  formation  with  the  exception  of 
HUVECs (where the absence of syncytia reflects low transfec-
tion efficiency, as confirmed using a CMV-GFP plasmid, data not 
shown).  In  contrast,  following  infection  with  Ad-eTie1-GALV 
syncytium  formation  was  observed  exclusively  in  HUVECs 
with  no  observable  syncytia  in  any  of  the  nonendothelial  cell 
lines tested (right panel images, Figure 2a). In order to provide 
quantitative  analysis  of  fusion  activity  in  different  cell  lines,  a 
fusion index was calculated for each experimental condition as 
described in the methods section. The average fusion indexes for 
MRC5v2, HT1080, and PC-3 cells following transfection with the 
CMV-driven, GALV-expressing plasmid were 0.22, 0.09, and 0.13, 
respectively (Figure 2a). The average fusion index for HUVECs 
following infection with Ad-eTie1-GALV was 0.10 (Figure 2a), 
whereas in MRC5v2, HT1080, and PC-3 cells it was 0.
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Figure 2  Ad-etie1-GAlV mediates extensive syncytium formation in endothelial cells but not in cells of epithelial or mesenchymal origin. (a) 
HUVEC, MRC5v2, HT1080, and PC­3 cells at 70% confluency were transfected with a CMV­driven GALV­expressing plasmid (left panel images) or 
infected with Ad­eTie1­GALV at 5,000 vp/cell (right panel images). Phase­contrast images were taken at 24 hours postinfection. Typical multinucle­
ated syncytial structures are indicated by arrows. (b) GALV mRNA production was restricted to endothelial cells infected with Ad­eTie1­GALV. A range 
of cell lines including those of endothelial, epithelial, and mesenchymal origin were infected, total cellular RNA from each sample was recovered and 
the levels of GALV transcript were quantified by RT­QPCR. (c) Ad infectivity in each cell line was measured by harvesting cells at 24 hours postinfection 
with Ad­eTie1­GALV at 5,000 vp/cell, followed by DNA extraction and QPCR to quantify adenoviral genome copy numbers. Results are presented as 
an average of triplicates ± SD. Statistical analysis was performed using one­way ANOVA Tukey’s multiple comparison test for all experimental groups. 
Ad, adenovirus; ANOVA, analysis of variance; CMV, cytomegalovirus; GALV, gibbon ape leukemia virus; HUVEC, human umbilical vein endothelial cell; 
KDR, kinase insert domain receptor; RT­QPCR, reverse­transcription real­time quantitative PCR.70  www.moleculartherapy.org  vol. 19 no. 1 jan. 2011     
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To  quantify  differential  expression  of  GALV,  mRNA  levels 
were determined by reverse-transcription real-time quantitative 
PCR (RT-QPCR) (Figure 2b). At 24 hours postinfection ~8.2 × 107 
GALV transcripts were obtained from infection of 10,000 HUVECs 
with Ad-eTie1-GALV at 5,000 vp/cell, whereas GALV mRNA was 
undetectable  in  all  other  cell  lines.  This  equates  to  ~19  GALV 
mRNA molecules from each virus genome, and ~8,200 transcripts 
per HUVEC. Statistical analysis confirms significant differences 
between transcript levels found in HUVECs versus all epithelial 
cell lines (P < 0.001 for all groups). Ad-Luc   infection of each cell 
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line served as negative controls for the design of GALV-specific 
primers and probe; no GALV mRNA was detected in these con-
trols. To account for possible differences in virus infectivity in dif-
ferent cell lines, viral genome copy numbers were determined at 24 
hours postinfection by real-time QPCR. No significant difference 
in the levels of Ad-eTie1-GALV associated with each cell line was 
detected (Figure 2c). These results demonstrate the strict endothe-
lial specificity of the CMV enhancer-Tie1 promoter system.
Heterocellular endothelial/epithelial syncytium 
formation induced by endothelial infection  
with Ad-etie1-GAlV in vitro
Coculturing  experiments  were  performed  to  test  whether 
Ad-eTie1-GALV  could  induce  fusion  between  two  cell  types. 
Coculturing of Ad-Luc infected HUVECs with each nonendothe-
lial cell line resulted in the maintenance of morphologically dis-
tinct mixed cell populations (left panel images, Figure 3a). In 
contrast,  widespread  heterocellular  syncytium  formation  was 
observed within 12 hours of the addition of uninfected PC-3, 
HCT116, or HEK 293 cells to HUVECs that had been preinfected 
with  Ad-eTie1-GALV  (right  panel  images  in  Figure  3a).  The 
average fusion indexes (F) for PC-3, HCT116, and HEK 293 cells 
cocultured with HUVECs preinfected with Ad-eTie1-GALV were 
0.59, 0.38, and 0.21, respectively. For Ad-Luc the F value was 0.
In  order  to  characterize  the  composition  of  the  syncytia 
formed under such mixed culture conditions PC-3 cells were visu-
alized using an antibody against epithelial cell adhesion molecule 
(EpCAM, in green), and HUVECs preinfected with Ad-eTie1-
GALV were visualized using an antibody against CD31 (in red). 
When the Ad-Luc control was used only single cells stained either 
red or green were observed (Figure 3b). However, abundant syn-
cytial structures were apparent when HUVECs were preinfected 
with Ad-eTie1-GALV (Figure 3c). An image gallery of these struc-
tures is shown in Figure 3d, they share the features of multinucle-
ation (as shown by DAPI) and are comprised of both HUVEC 
endothelial (red) and PC-3 epithelial cells (green). Single stained 
PC-3 and HUVEC which have yet to be incorporated into the syn-
cytia are also apparent at the margins of these images. These data 
confirmed the ability of GALV-expressing HUVECs to form het-
erocellular syncytia with a range of tumor cell types.
transactivation of virus replication upon 
heterocellular syncytium formation in vitro
The activation of an oncolytic Ad within the endothelial nucleus of 
a heterocellular syncytium would generally require the conversion 
of the nucleus into a site for virus production by the nuclear import 
of tumor-associated cytoplasmic factors. To assess the feasibility 
of this approach, HUVECs were infected with the E1/E3-deleted 
Ad-eTie1-GALV  or  Ad-Luc  virus  before  coculture  with  HEK 
293 cells, which stably express adenoviral E1 gene products and 
should be capable of transcomplementing missing viral functions 
in these replication-deficient vectors. Mixed   cultures containing 
HUVECs preinfected with the control Ad-Luc virus did not give 
observable cytopathic effect (Figure 4a) and distinct HUVEC and 
HEK 293 populations were still observable after 72 hours. In con-
trast complete cytopathic effect was achieved 72 hours after mix-
ing Ad-eTie1-GALV-infected HUVECs with uninfected HEK 293 
cells (Figure 4a), where the disappearance of syncytia at 48 and 
72 hours is linked to the raised cytotoxic replication (Figure 4b). 
QPCR analysis of the number of Ad genome copies in the culture 
supernatant  revealed  an  ~10,000-fold  increase  in  Ad  genomes 
between 24 and 72 hours when using Ad-eTie1-GALV, whereas 
Ad-Luc gave only a 100-fold rise over the same period (Figure 4b). 
This statistically significant difference (P < 0.001) in genome copy 
numbers obtained from cocultures with or without GALV demon-
strate the successful transactivation of the   replication-deficient 
virus in heterocellular syncytia.
endothelial-directed GAlV expression leads to target 
cell infection and enhanced virus replication in vivo
The feasibility of testing the Ad-eTie1-GALV vector in a murine 
model was demonstrated by the successful induction of murine 
endothelial  (bEnd.3)  fusion  to  human  epithelial  (HEK  293) 
cells  in  vitro.  When  Ad-Luc-infected  bEnd.3  cells  were  mixed 
with uninfected HEK 293 cells no multinucleated syncytia were 
obtained (Figure 5a). However, when uninfected HEK 293 cells 
were mixed with bEnd.3 cells which had been preinfected with 
Ad-eTie1-GALV syncytia were obtained (Figure 5b), demonstrat-
ing murine (i.e., Pit-1 negative) endothelial cells producing GALV 
could undergo fusion with human HEK 293 (Pit-1 positive) cells.
The demonstration of fusion-mediated viral transduction of 
noninfected cells in vitro encouraged the testing of this strategy 
in  vivo  to  provide  a  more  relevant,  three-dimensional  model. 
Ad-Luc or Ad-eTie1-GALV was given i.v. at 3 × 1010 vp/animal to 
mice-bearing subcutaneous HEK 293 xenografts, or control PC-3 
tumors which do not express E1 gene products and therefore can-
not provide transcomplementation. Xenografts and tumors were 
harvested  after  48  hours.  Measurement  of  Ad  genomes  copies 
in the HEK 293 xenografts revealed a threefold higher level of 
Ad-eTie1-GALV (1.2 × 108/xenograft) than Ad-Luc (4.0 × 107vp/
xenograft) (P = 0.008), providing evidence for enhanced access 
of the replication-deficient virus to HEK 293 cells in the presence 
of GALV expression (Figure 5c). This likely to be a conservative 
measure  of  the  extent  to  which  endothelial  GALV  expression 
has increased virus access to xenografted cells, as plaque assays 
revealed that the titer of the control Ad-Luc used here was approx-
imately tenfold higher than that of Ad-eTie1-GALV. In contrast 
to  the  significantly  higher  levels  of  Ad-eTiel-GALV  compared 
Figure 3  Ad-etie1-GAlV induces heterocellular endothelial–  epithelial syncytium formation in vitro. Subconfluent HUVECs were infected at 
5,000 vp/cell with Ad­Luc or Ad­eTie1­GALV and subsequently cocultured with uninfected PC­3, HCT116, or HEK 293 cells. (a) Phase­contrast images 
of syncytia (indicated by arrows) formed between HUVECs and each epithelial cell line in the presence of endothelial­  specific GALV expression. (b) 
Fluorescence microscopy of PC­3 cells cocultured with HUVECs preinfected with Ad­Luc. (c,d) Fluorescently labeled heterocellular syncytia obtained 
from cocultures of PC­3 cells with HUVECs preinfected with Ad­eTie1­GALV. An anti­CD31 primary antibody was used as an endothelial­specific 
marker, in combination with an Alexa Fluor 594­conjugated secondary antibody. An anti­EpCAM primary antibody was used as an epithelial­specific 
marker, in combination with an Alexa Fluor 488­conjugated secondary antibody (see Materials and Methods section). Ad, adenovirus; CMV, cyto­
megalovirus; GALV, gibbon ape leukemia virus; HEK 293, human embryonic kidney 293; HUVEC, human umbilical vein endothelial cell; KDR, kinase 
insert domain   receptor; RT­QPCR, reverse­transcription real­time quantitative PCR.72  www.moleculartherapy.org  vol. 19 no. 1 jan. 2011     
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to Ad-Luc found in HEK 293 xenografts, there was no statisti-
cally significant difference between the quantities of the viruses 
in the control E1-deficient PC-3 tumors (P = 0.38) (Figure 5d), 
demonstrating that the higher levels of Ad-eTie1-GALV was a 
result of increased virus access to and replication in HEK 293 
xenografts. Since GALV expression is endothelial-selective, our 
data suggest that virus infection of tumor-associated endothelial 
cells has enabled GALV-mediated spread of the virus to adjacent 
  xenografted epithelial cells.
In order to confirm the in vivo formation of   heterocellular 
syncytia  between  murine  endothelium  and  HEK  293  cells, 
immunohistochemistry of tissue cross-sections was performed. 
Distinct  endothelial  (red)  and  epithelial  (green)  cells  were 
observed  in  xenograft  cross-sections  from  Ad-Luc  treated 
  animals (Figure 6a) with no evidence of colocalized staining. 
However, dual-stained, multinucleated structures were observed 
in sections obtained from animals treated with Ad-eTie1-GALV 
(Figure  6b).  Heterocellular  structures  were  rare;  examination 
of  50  nonconsecutive  tissue  sections  afforded  observations  of 
four dual-stained syncytia. The areas of intense yellow staining 
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Figure 5  Heterocellular syncytium formation provides viral access 
to target cells and elicits transactivation of virus replication in vivo. 
Murine endothelial to human epithelial fusion was tested in vitro by the 
mixing of uninfected HEK 293 cells with bEnd.3 cells which had been 
preinfected with (a) Ad­Luc or (b) Ad­eTie1­GALV (5,000 particles per 
cell, 2 hours). Phase­contrast images taken at 24 hours after mixing dif­
ferent cell populations. For in vivo studies, female SCID mice (Charles 
River) were implanted subcutaneously with 2.5 × 106 HEK 293 or PC­3 
cells; xenografts were allowed to develop to ~4 mm in diameter before 
i.v. administration of either the control Ad­Luc virus or Ad­eTie1­GALV 
at 3 × 1010 vp/animal. Xenografts were harvested at 48 hours after virus 
injection; tissues were homogenized and genomic DNA was extracted. 
Ad  genomes  present  in  (c)  HEK  293  xenografts  or  (d)  control  PC­3 
tumors were quantified by QPCR. Data represent mean values ± SE of 
the mean; statistical analyses were performed by t­tests (n = 7, except 
for Ad­eTie1­GALV in PC­3 where n = 6); **P < 0.01, †P > 0.05. Ad, ade­
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24
hours
48
hours
72
hours
72
hours
48
hours
24
hours
1.0 × 105
1.0 × 104
1.0 × 103
1.0 × 102
b
a
* * *
Ad-Luc Ad-eTie1-GALV
F
o
l
d
-
i
n
c
r
e
a
s
e
 
i
n
 
A
d
 
g
e
n
o
m
e
 
c
o
p
i
e
s
 
Ad-Luc Control Ad-eTie1-GALV
Figure  4  transactivation  of  virus  replication  upon  heterocellular 
syncytium formation permits fusion-dependent transduction of HeK 
293 cells and destruction of cell culture monolayer. HUVECs (50% 
confluency) were preinfected with either Ad­Luc control or Ad­eTie1­
GALV at 5,000 vp/cell and washed thoroughly at the completion of the 
2­hour infection. Uninfected HEK 293 cells were added to the endothe­
lial cell cultures at 24 hours after HUVEC infection to give a 1:1 ratio of 
HUVEC:HEK 293. Culture supernatant was removed and replaced with 
fresh media at 24 hours after the addition of HEK 293 cells. (a) Phase­
contrast images taken at 24, 48, and 72 hours after mixing different cell 
populations. (b) Samples of culture supernatant were taken at 24 and 72 
hours after mixing the two cell populations for the determination of viral 
genome copy numbers by QPCR. Results are expressed as fold­increase 
in genome copies from the 24 to the 72­hour time point. All data points 
are presented as averages of triplicates ± SD. Statistical analyses were 
performed by t­tests (n = 3); ***P < 0.001. Ad, adenovirus; HEK 293, 
human embryonic kidney 293; HUVEC, human umbilical vein endothe­
lial cell; QPCR, quantitative PCR.Molecular Therapy  vol. 19 no. 1 jan. 2011  73
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(see  arrows)  are  indicative  EpCAM  and  CD31  colocalization 
made possible by the GALV-mediated fusion of epithelial cells 
to endothelial cells. These data confirm the GALV-mediated for-
mation  of  mouse  endothelial-human  epithelial  heterocellular 
syncytia.
dIscussIon
The  tumor-associated  vasculature  presents  a  highly  accessible 
target for vp circulating in the bloodstream,3,26 enabling active 
targeting approaches.27 In the present study, we explored a strat-
egy to enhance viral vascular penetration in order to increase 
the therapeutic index of a systemically delivered Ad. We tested 
the hypothesis that vascular transcriptional targeting and subse-
quent induction of site-specific syncytium formation can be com-
bined to turn a major structural obstacle imposed by the tumor 
endothelium into an entry route toward tumor cells. A hybrid 
viral enhancer/human promoter system encompassing the CMV 
enhancer and the Tie1 promoter was used to mediate conditional 
activation of GALV expression upon Ad infection of proliferating 
endothelium. Using this vector (Ad-eTie1-GALV) we achieved 
tight  endothelial-selective  transcriptional  activity  and  targeted 
induction of endothelial–epithelial fusion in  vitro  and  in  vivo, 
presenting the first demonstration of exploiting a viral FMG to 
induce  heterocellular  syncytium  formation  in  order  to  create 
access to target tumor cells.
Upon endothelial infection and the induction of heterofusion, 
the ability of a GALV-expressing Ad to successfully replicate in het-
erocellular syncytia is crucial for subsequent vp dissemination. As 
there is no internuclear spread of Ad DNA upon GALV-induced 
syncytium formation,28 the ability of transactivating factors to be 
imported into nuclei-containing Ad genomes would be essential for 
triggering replication. Tumor-associated endothelial cells are non-
cancerous and should therefore be unable to support the replication 
of conditionally replicating Ad; therefore, the capacity of hetero-
cellular syncytia to support virus transactivation following fusion 
of a virus-infected, nonpermissive cell type with a permissive cell 
type was investigated. The initiation of Ad replication upon fusion 
between endothelial cells infected with the E1, E3-deleted vector 
Ad-eTie1-GALV and cocultured permissive HEK 293 cells dem-
onstrated the successful transactivation of the replication-defective 
virus in vitro. Dramatically increased (~2-log) levels of virus were 
recovered from these cocultures compared to those infected with 
a luciferase-expressing control vector, correlating with more rapid 
development of cytopathic effect. This is a novel demonstration 
that the cytoplasmic factors of an epithelial cell can be shared by 
the nuclei of an Ad-infected endothelial cell in a heterocellular syn-
cytium, thereby driving virus replication, spread, and cell killing. 
These data therefore support the hypothesis that GALV-induced 
heterofusion may promote target cell transduction and subsequent 
vp dissemination. The in vitro data encouraged further testing of 
the hypothesis that heterofusion may aid the penetration of sys-
temically administered adenoviral vectors through tumor-associ-
ated endothelium in an in vivo setting. Levels of Ad-eTie1-GALV 
found in HEK 293 xenografts were significantly higher than levels 
of the control Ad-Luc virus at 48 hours post-i.v. administration, 
whereas similar amounts of the two viruses were recovered from 
corresponding control PC-3 tumors, suggesting enhanced access 
of the replication-defective vector to HEK 293 xenografts result-
ing from conditionally activated GALV expression. Identification 
of costained heterocellular syncytia in cross-sections of xenografts 
harvested from HEK 293-bearing animals treated with Ad-eTie1-
GALV confirmed that the endothelial–epithelial fusion evidenced 
in vitro can also be achieved in vivo. The complete absence of such 
syncytial structures in Ad-Luc-treated animals indicated that the 
raised levels of Ad-eTie1-GALV in HEK 293 xenografts can be 
accounted for by such fusion. Our data therefore suggests that 
heterofusion assists target cell transduction in vivo and results in 
enhanced virus replication. It is worth noting that the process of 
heterofusion may be suboptimal in the present in vivo model, as 
evidenced by the fact that the occurrence of dual-stained, multinu-
cleated heterocellular syncytia was infrequent. As the Pit-1 recep-
tor required for GALV-mediated fusion is absent on murine cells,10 
any host stromal cells such as pericytes and fibroblasts within the 
xenograft will create a barrier to limit the interaction of infected 
endothelial cells with the HEK 293 cells. Another possible fac-
tor limiting the efficiency of this model system is the abortive or 
poor replication efficiency of human Ads in mouse cells29–31 due to 
repression of viral E1A enhancer activity32 and defects in the syn-
thesis of structural proteins.33 Such repression could still occur to 
some extent despite the E1 gene products being provided in trans 
by the HEK 293 component of the syncytium. Despite the limi-
tations of the present model system, we have demonstrated that 
  heterocellular   syncytium formation following infection of endothe-
lial cells rendered fusion-dependent transduction of HEK 293 cells 
in vitro and HEK 293 xenografts in vivo, enabling transactivation 
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Figure  6  detection  of  heterocellular  syncytia  formed  between 
murine  vascular  endothelium  and  HeK  293  cells.  Xenografts  har­
vested at 48 hours post­treatment with Ad­Luc or Ad­eTie1­GALV were 
snap­frozen and cryosections were prepared. Subsequent immunofluo­
rescence labeling of murine endothelium and HEK 293 cells was carried 
out on multiple nonconsecutive tissue cross­sections, providing observa­
tions of murine vasculature in HEK 293 xenografts following i.v. injection 
of (a) Ad­Luc as well as dual­stained, multinucleated structures unique 
to xenografts harvested from animals receiving (b) Ad­eTie1­GALV. The 
murine endothelium was stained red and human epithelial cells were 
stained green using conditions described in materials and methods. Ad, 
adenovirus; GALV, gibbon ape leukemia virus; HEK 293, human embry­
onic kidney 293.74  www.moleculartherapy.org  vol. 19 no. 1 jan. 2011     
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of virus replication and resulting in significantly increased virus 
production in both settings. We have therefore provided the first 
  demonstration of exploiting heterocellular fusion as a means to 
aid viral vascular penetration, leading ultimately to enhanced tar-
get cell transduction. This presents a novel therapeutic approach 
to overcome a major physical barrier to the systemic delivery of 
oncolytic viruses. This strategy may enable conditional activation 
of FMG expression under tumor-specific conditions and maximize 
the therapeutic potential of the bioavailable fraction of a   circulating 
oncolytic agent.
MAterIAls And MetHods
Cell lines and culture. HUVECs (Lonza, Basel, Switzerland) and human 
adult  dermal  microvascular  endothelial  cells  (HMVECs;  Cambrex, 
Walkersville,  MD)  were  cultured  in  EGM-2  endothelial  cell  growth 
medium supplemented with EGM-2 bullet kit (Lonza). Human embryonic 
kidney epithelial 293 cells (HEK 293; American Type Culture Collection, 
Manassas, VA), PC-3 (American Type Culture Collection), SW480 (kindly 
provided by Prof Richard Iggo, University of St Andrews, St Andrews, UK), 
MRC5V2 (kindly provided by Dr Richard Wade-Martins, University of 
Oxford, Oxford, UK) and HT1080 (kindly provided by Prof Eric Bernhard, 
University of Oxford), were cultured in high-glucose Dulbecco’s modified 
Eagle’s medium (PAA Laboratories, UK), supplemented with 10% fetal calf 
serum (PAA Laboratories, Pasching, Austria), and 1% penicillin (10,000 
units/ml)-streptomycin  (10 mg/ml)  (pen/strep)  solution  (Sigma,  Dorset, 
UK). All cells were cultured at 37 °C in a humidified, 5% CO2 environment. 
Routine maintenance of cells and preparation for experiments involving cell 
cultures were performed using aseptic techniques.
Molecular engineering and virus production. The human KDR23,24 and 
Tie115  promoters  were  isolated  by  PCR  from  genomic  DNA  extracted 
from HUVECs. Oligonucleotide primer sequences used for PCR are: For 
KDR—5′ GTC GAC AAC AAA GTT GTT GCT CTG GGA TGT TCT 
C 3′ and 5′ GGG AGC CGG TTC TTT CTC 3′; for Tie1—5′ GTC GAC 
CGG CAA AAT GAA TGA CAC CTG GCA GAC 3 and 5’ TAC TCC 
AGA GGC CGA CCC AG 3′. Resultant PCR products were inserted into 
TOPO-XL cloning vectors (Invitrogen, Paisley, UK).
Endothelial promoter (Tie1/KDR) driven luciferase or GALV-expressing 
Ads were generated based on the AdEasy System (MP Biomedicals, Solon, 
OH). Luciferase (firefly Photinus pyralis luciferase; Promega, Madison, WI) 
and GALV (a kind gift from Prof Richard Vile, Mayo Clinic, Rochester, MN) 
were ligated downstream of each promoter in TOPO-XL. The resultant 
four  constructs  containing  KDR/Tie1  upstream  of  luciferase  or  GALV 
were ligated into the multiple cloning site of the pShuttle transfer vector 
(AdEasy  recombinant  Ad  production  kit;  MP  Biomedicals).  The  CMV 
major immediate-early enhancer was PCR-amplified from the pShuttle-
CMV vector (AdEasy recombinant Ad production kit; MP Biomedicals) 
and subcloned upstream of Tie1-GALV in pShuttle. The resultant pShuttle 
vectors containing the five (enhancer)-promoter-transgene constructs were 
subjected to recombination with the AdEasy-1 plasmid, which contains 
the E1 and E3-deleted human Ad type 5 genome. Correct sequences of all 
constructs were confirmed by DNA sequencing. Successful recombinants 
were linearized by digestion with PacI and transfected into E1-expressing 
HEK 293 cells using a calcium-phosphate transfection protocol. Resultant 
viruses were double-purified by cesium chloride gradient centrifugation. 
Virus DNA concentrations were determined by PicoGreen assay (PicoGreen, 
dsDNA quantitation reagent; Invitrogen) and virus titers determined by 
plaque assay, values of 3.3 × 1010 Ad-Luc and 1.7 × 1010 Ad-eTie1-GALV 
plaque-forming units/ml.
Calculating  fusion  indexes  for  various  syncytia  and  heterocellular 
  syncytia. In order to provide quantitative analysis of fusion activity in 
different cell lines or mixed endothelial/epithelial cultures after   transfection 
with a CMV-driven GALV-expressing plasmid or infection with Ad-eTie1-
GALV, a fusion index was calculated by counting the number of cells and 
nuclei present in a microscopic field according to the equation: F (fusion 
index) = 1 − (C/N), where C is the number of cells and N is the number of 
nuclei in a field after fusion.34 Hence where each cell contains one nucleus 
the F value equals 0. As syncytia formation causes an increase in the num-
ber of nuclei per cell the F value tends toward 1. For each experimental 
condition, the fusion index was determined by taking the average of three 
F values obtained from three different microscopic views.
Real-time  QPCR.  Real-time  QPCR  was  used  to  detect  and  quantify 
adeno  viral DNA in extracted DNA samples using an ABI 7000 Sequence 
Detection System and software. Amplification of an 84 base pair fragment 
of the Ad fiber gene was carried out using primers, probes, and conditions 
as outlined by Green et al.26.
RT-QPCR. RT-QPCR was performed where it was necessary to quan-
tify  levels  of  the  GALV  transcript.  Total  cellular  RNA  was  harvested 
from HUVEC, PC-3, MRC5V2, and HT1080 cells infected with either 
Ad-eTie1-GALV or the control Ad-Luc at 24 hours postinfection, using 
the mirVana miRNA isolation kit (Applied Biosystems, Warrington, UK). 
One-step RT QPCR was performed using the TaqMan RNA-to-CT 1-step 
kit (Applied Biosystems) and an ABI 7000 Sequence Detection System 
and software according to the manufacturer’s instructions. GALV-specific 
primers: 5′ CAA GCC TCC AGA TCG CCA TA 3′ and 5′ ACC TCG GAC 
AGG GAA GTC AGT 3′, and probe: 5′ CCC TCC AAG ACT CAG 3′ were 
employed. An identical set of conditions were prepared for extraction of 
total viral genomic DNA at 24 hours postinfection. A standard curve was 
constructed from samples of known GALV DNA concentrations and used 
to derive transcript copy numbers assuming 100% reverse transcription 
efficiency; this data therefore represents minimum GALV mRNA levels 
accounted for by RT-QPCR. All conditions were tested in triplicate and 
results expressed as the number of GALV mRNA molecules per virus 
genome detected.
In vitro luciferase assay. HUVEC, human microvascular endothelial cell, 
and SW480 cells were seeded at 6,000 cells/well in 96-well plates 24 hours 
before infection with Ad-KDR-Luc, Ad-Tie1-Luc, or Ad-Luc at 1,000 vp/
cell. Cells were lysed in luciferase cell culture lysis reagent (Luciferase 
Assay  System;  Promega)  and  freeze-thawed  at  48  hours  postinfection. 
Relative promoter activities as reflected by luciferase expression and light 
emission  upon  addition  of  luciferase  assay  substrate  (Luciferase  Assay 
System;  Promega)  were  measured  using  a  Lumat  LB  9507  tube  lumi-
nometer (Berthold Technologies, Harpenden, UK). Adenoviral DNA was 
extracted for each sample and quantified by QPCR. Luciferase readings 
were standardized according to viral genome copy numbers in each sample 
to take into account the differences in infectivity and virus uptake by each 
cell line. All conditions were tested in quadruplicate and results expressed 
as relative light units/genome copy.
Immunocytochemistry.  HUVECs  cultured  in  glass-bottom  dishes 
(Electron Microscopy Sciences, Hatfield, PA) were infected with either 
Ad-eTie1-GALV or the control Ad-Luc (10% confluency at time of infec-
tion to ensure maximal cell growth) 24 hours before addition of unin-
fected cells types (HUVEC or PC-3) to generate syncytia in the presence 
of  GALV.  Cells  and  syncytia  were  subsequently  dehydrated  and  fixed 
(Cell-Fixx  Spray  fixative;  Thermo  Fisher  Scientific,  Loughborough, 
UK)  for  immunocytochemical  manipulations.  Fluorescent  labeling  of 
the cytoskeleton (α-tubulin) was achieved using a fluorescein isothio-
cyanate-conjugated  anti-α-tubulin  antibody  (Sigma).  For  characteriza-
tion  of  heterocellular  syncytia,  cell  type-specific  primary  antibodies 
and  fluorophore-  conjugated  secondary  antibodies  were  employed.  An 
anti-CD31  primary  antibody  (mouse  antihuman  CD31,  isotype  IgG1; Molecular Therapy  vol. 19 no. 1 jan. 2011  75
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Abcam, Cambridge, UK) was used as an endothelial-specific marker, in 
  combination with an Alexa Fluor 594-  conjugated goat anti-mouse IgG1 
secondary    antibody  (Invitrogen,  UK).  An  anti-Epcam  primary  anti-
body (rabbit antihuman epithelial cell adhesion molecule, isotype IgG; 
Abcam) was used as an epithelial-  specific marker, in combination with 
an  Alexa  Fluor®  488-conjugated  goat  anti-rabbit  IgG  secondary  anti-
body  (Invitrogen).  Slides  were  prepared  for  microscopic  examination 
using Vectashield mounting media containing DAPI (Vector Laboratories 
Ltd, UKK).
Immunohistochemistry. HEK 293 xenografts were harvested from Ad-Luc 
or Ad-eTie1-GALV treated animals at 96 hours post-i.v. injection; sections 
were prepared from snap-frozen tissues and rehydrated prior to immuno-
labeling  procedures.  Mouse  endothelium  was  stained  using  a  rat  anti-
mouse CD34 primary antibody (Abcam) coupled with an Alexa Fluor® 568 
goat anti-rat IgG secondary antibody (Invitrogen, UK). Human epithelial 
tumour  cells  were  stained  using  conditions  described  for  immunocy-
tochemistry. Processed slides were stabilized with Vectashield mounting 
media containing DAPI.
In vivo studies. All animal experimentation was performed in accordance 
with the terms of UK Home Office guidelines and the UKCCCR Guidelines 
for the Welfare of Animals in Experimental Neoplasia. For studies of viral 
transactivation using HEK 293 xenografts, female severe combined immune 
deficiency beige mice (Charles River, Margate, UK) were injected subcutane-
ously with 2.5 × 106 HEK 293 or E1-negative control PC-3 cells. Xenografts 
were allowed to develop to ~4 mm in diameter. HEK 293 or PC-3 xenograft-
bearing animals were pretreated with clodronate liposomes (100 µl of origi-
nal formulation per animal; ClodronateLiposomes.org) 24 hours before i.v. 
injection with 3 × 1010 particles of either Ad-eTie1-GALV or Ad-Luc. All 
i.v. injections of viruses were performed via the tail vein in a total volume of 
100 µl. Xenografts were harvested at 48 hours after virus injection. All tissues 
were homogenized in lysis buffer (Luciferase Assay System; Promega) using 
a motorized homogenizer (Ultra Turrax IKA T18 Basic; Fisher Scientific) to 
obtain a 300 mg (wet weight)/ml homogenate, from which 180 µl was taken 
for DNA extraction. A standard curve was prepared from serial dilutions of 
Ad-eTie1-GALV spiked into a 300 mg/ml mouse tissue homogenate. QPCR 
analyses were performed as described previously.
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